

CUREVAC NV

ISIN: NL0015436031

WKN: N2451R105

Overview

2024/07/18 12:02:44

Price

3.342 EUR

Difference ▲ 0.36% (0.01)

General attributes

ISIN NL0015436031

Symbol CVAC

Exchange Frankfurt

Currency EUR

Sector Chemical / Pharmaceutical / Health

Security type Stock

Market cap (m) 748 EUR

Benchmark GERMANY DAX

Market data

Bid (Bid size) 3.326 EUR (602)

Ask (Ask size) 3.358 EUR (596)

Open 3.38 EUR

High 3.38 EUR

Low 3.31 EUR

Close (prev. day) 3.33 EUR

VWAP 3.33435 EUR

Volume (pcs) 4,787

Trading volume 15,961.55

Number of trades 8

Last size 1,402

Futures and Options

Related Futures -

Related Options -

PDF Downloads

Company report: CUREVAC NV



5Y



Information about previous performance does not guarantee future performance.

Source: FactSet

Recent research

| on sector | | on market | |
|------------|--|-----------------------|----------|
| Date | | Headline | Download |
| 2024/07/12 | | Global Equity Ratings | |
| 2024/06/21 | | Global Equity Ratings | |
| 2024/06/14 | | Global Equity Ratings | |
| 2024/05/29 | | Global Equity Ratings | |
| 2024/04/26 | | Global Equity Ratings | |

Details

2024/07/18 12:02:44

Price

3.342 EUR

Difference ▲ 0.36% (0.01)

General attributes

ISIN NL0015436031

Symbol CVAC

Exchange Frankfurt

Currency EUR

Sector Chemical / Pharmaceutical / Health

Security type Stock

Market cap (m) 748 EUR

Benchmark GERMANY DAX

Market data

Bid (Bid size) 3.326 EUR (602)

Ask (Ask size) 3.358 EUR (596)

Open 3.38 EUR

High 3.38 EUR

Low 3.31 EUR

Close (prev. day) 3.33 EUR

VWAP 3.33435 EUR

Volume (pcs) 4,787

Trading volume 15,961.55

Number of trades 8

Last size 1,402

Performance and Risk

| | 6m | 1Y | 3Y |
|-------------|--------|---------|---------|
| Perf (%) | -3.48% | -62.20% | -92.11% |
| Perf (abs.) | -0.12 | -5.48 | -38.90 |
| Beta | 0.84 | 0.85 | 0.90 |
| Volatility | 74.88 | 71.90 | 74.52 |

5Y



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

| | |
|---------------------------------------------|------------------------|
| Ø price 5 days Ø volume 5 days (pcs.) | 3.178 EUR (22,221) |
| Ø price 30 days Ø volume 30 days (pcs.) | 3.298 EUR (39,976) |
| Ø price 100 days Ø volume 100 days (pcs.) | 3.038 EUR (28,543) |
| Ø price 250 days Ø volume 250 days (pcs.) | 4.526 EUR (20,392) |
| YTD High date | 4.808 EUR (2024/06/06) |
| YTD Low date | 2.056 EUR (2024/04/25) |
| 52 Weeks High date | 9.120 EUR (2023/08/16) |
| 52 Weeks Low date | 2.056 EUR (2024/04/25) |

Arbitrage views

| Exchange ⊕ | Date | Time | Price | Trading volume (mio.) | Number of trades |
|-------------------------|------------|-------|-----------|-----------------------|------------------|
| Xetra | 2024/07/18 | 12:12 | 3.348 EUR | 0.07 | 138 |
| Vienna Stock Exchange | 2024/07/18 | 11:00 | 3.354 EUR | 0.00 | 1 |
| Tradegate | 2024/07/18 | 12:23 | 3.35 EUR | 0.23 | 99 |
| Stuttgart | 2024/07/18 | 12:16 | 3.34 EUR | 0.02 | 12 |
| Nasdaq | 2024/ | 22:00 | 3.65 USD | 3.67 | 8,778 |

| | | | | | | | |
|---------------------------------------------------|----------------|-------|-------|-----|------|--|---|
| | 07/17 | | | | | | |
| Munich | 2024/ 07/18 | 08:07 | 3.302 | EUR | 0.00 | | 1 |
| London Stock Exchange European Trade Reporting | 2024/ 07/18 | 10:00 | 3.635 | USD | 0.00 | | 1 |
| Hanover | 2024/ 07/18 | 10:24 | 3.328 | EUR | 0.00 | | 2 |
| Hamburg | 2024/ 07/18 | 08:00 | 3.296 | EUR | 0.00 | | 1 |
| Frankfurt | 2024/ 07/18 | 12:02 | 3.342 | EUR | 0.02 | | 8 |
| Euronext Milan MTF Trading After Hours | 2024/ 07/17 | 17:44 | 3.174 | EUR | 0.00 | | 1 |
| Euronext Milan MTF Global Equity Market | 2024/ 07/17 | 17:44 | 3.174 | EUR | 0.00 | | 1 |
| Duesseldorf | 2024/ 07/18 | 09:30 | 3.312 | EUR | 0.00 | | 2 |
| Berlin | 2024/ 07/18 | 08:08 | 3.292 | EUR | 0.00 | | 1 |

Company profile

Company Logo



Contact Details

CUREVAC NV

--

Friedrich-Miescher-Strasse 15 - 72076
Tübingen

Telefon: +49-7071-9883-0

Fax: +49-7071-9883-1101

E-mail: info@curevac.com

PDF Downloads

Company report: CUREVAC NV



Company Profile

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

Members of Management Board

Alexander Zehnder Chairman of Managing Board

Malte Greune Member of Executive Committee

Myriam Mendila Member of Executive Committee

Pierre Kemula Member of Executive Committee

Thaminda Ramanayake Member of Executive Committee

Board of directors

Baron Jean Stéphane Chairman of Supervisory Board

Debra Stephanie Barker Member of Supervisory Board

Klaus Schollmeier Member of Supervisory Board

Mathias Hothum Member of Supervisory Board

Viola Bronsema Member of Supervisory Board

Birgit Hofmann Member of Supervisory Board

Craig Tooman Member of Supervisory Board

Michael Brosnan Member of Supervisory Board